SOURCE: Pronova BioPharma ASA

April 15, 2008 17:16 ET

Revision of amortisation profiles

LYSAKER, NORWAY--(Marketwire - April 15, 2008) - Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or "the company") has, with effect from 1 January 2008, changed the amortisation profiles within the estimated total useful life period for patents, customer contracts and customer relations acquired in the business combination in May 2006. Estimated amortisation charges of identifiable intangible assets in 2008, after updated amortisation profiles are NOK 94.4 million. The assessed useful lives of these intangible assets are unchanged. The residual values, useful lives and the amortisation methods applied are subject to review on an annual basis.

Details are given in note 15 to the consolidated financial statements in the company's 2007 annual report, which has been published today and can be found at www.newsweb.no and www.pronova.com.


Copyright © Hugin AS 2008. All rights reserved.

Contact Information

  • For further information, please contact:
    Hilde H. Steineger
    Head of IR
    +47 48 00 42 40

    Morten Jurs
    CFO
    +47 22 53 49 10